Want to see CRDF full AI Analyst Report?
CRDF Stock Chart & Stats
$0.83
$0.02(2.30%)
At close: 4:00 PM EDT
$0.83
$0.02(2.30%)
Day’s Range― - ―
52-Week Range$0.76 - $3.31
Previous CloseN/A
Volume462.43K
Average Volume (3M)1.68M
Market Cap
$68.93M
Enterprise Value$54.85
Total Cash (Recent Filing)$34.52M
Total Debt (Recent Filing)$457.00K
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Oct 29, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding77,795,250
10 Day Avg. Volume2,518,065
30 Day Avg. Volume1,675,576
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.01Price Target Upside503.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.6
Revenue Forecast (FY)$256.44K
Bulls Say, Bears Say
Bulls Say
Phase 2 Efficacy And Registrational PathwayThe reported response advantage and favorable safety profile provide clinical validation for onvansertib in first-line RAS-mutated colorectal cancer. The planned Phase 3 design and regulatory discussions create a defined pathway toward potential approval and future commercial revenue.
Very Low Financial LeverageMinimal debt reduces solvency pressure and interest obligations while Cardiff advances its clinical programs. This gives the company greater flexibility to prioritize research spending and pursue additional financing without the constraints typically associated with a highly leveraged balance sheet.
Near-term Funding From Completed FinancingThe completed financing strengthens near-term liquidity and helps fund ongoing oncology development without relying immediately on another capital raise. Insider participation may also align stakeholders, although the equity-based structure increases dilution risk for existing shareholders.
Bears Say
Pre-commercial Business With Minimal RevenueCardiff lacks a recurring commercial product revenue base and remains dependent on successful clinical and regulatory execution before meaningful monetization. Large losses relative to revenue indicate that the current operating model cannot self-fund development or provide earnings stability.
Persistent Cash Burn And External Funding DependenceSustained cash outflows from research and development require repeated access to equity, debt, licensing, or partnership capital. If clinical timelines extend or financing conditions weaken, funding pressure could slow the pipeline and increase the cost or dilution associated with maintaining operations.
License Dispute Creates Intellectual-property RiskOnvansertib is Cardiff’s central development asset, so a dispute over the license could affect control of key intellectual property and program continuity. An adverse outcome could delay trials, increase legal and development costs, or undermine the asset’s eventual commercialization.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $0.76 and its highest was $3.31 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $68.93M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 70 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.02.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 77,795,250 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.01 (503.61% Upside)
$5.01 (503.61% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.71%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
CRDF Stock 12 Month Forecast
Average Price Target
$5.01
▲(503.61% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
2.89% Insiders
6.97% Mutual Funds
9.33% Other Institutional Investors
76.88% Public Companies and
Individual Investors